Yıl: 2021 Cilt: 8 Sayı: 2 Sayfa Aralığı: 195 - 201 Metin Dili: İngilizce DOI: 10.4274/jpr.galenos.2021.65768 İndeks Tarihi: 09-06-2022

Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients

Öz:
Aim: To investigate cardiac involvement in patients diagnosed with mucopolysaccharidosis type III (MPS III) in a university hospital in Turkey. Materials and Methods: This descriptive cross-sectional study was performed in a university hospital by examining the files of 49 MPS III patients who were admitted between January 1998 and December 2019. Results: The mean age of the participants was 12.24±5.21 years (range: 1-26). The mean age at which the patients underwent echocardiography was 6.90±4.82 years. MPS IIIA, IIIB, IIIC, and IIID subtypes were present in 24 (49.0%), 19 (38.8%), 5 (10.2%), and 1 (2.0%) patient, respectively. Among the MPS III patients who had echocardiographic evaluation (n=44), 32 patients (72.7%) had pathological cardiac findings, while 12 patients (27.3%) had normal cardiac findings on echocardiographic examination. The most common cardiac pathologies were those related to mitral valve [valve insufficiency 52.3% (n=27), valve thickening 43.2% (n=25), and prolapse 38.6% (n=23)]. Tricuspid insufficiency (34.8%, n=8) was seen only in MPS IIIA. Mitral insufficiency and aortic valve thickening were significantly more common among females (p=0.014, p=0.025, respectively). Conclusion: Patients with MPS III should be closely monitored for cardiac pathologies and especially mitral valve insufficiency, which are more prevalent among females.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Zhou J, Lin J, Leung WT, Wang L. A basic understanding of mucopolysaccharidosis: Incidence, clinical features, diagnosis, and management. Intractable Rare Dis Res 2020; 9:1-9.
  • 2. Coutinho MF, Lacerda L, Alves S. Glycosaminoglycan storage disorders: a review. Biochem Res Int 2012;2012:471325. doi: 10.1155/2012/471325
  • 3. Osipova LA, Kuzenkova LM, Namazova-Baranova LS, Gevorkyan AK, Podkletnova TV, Vashakmadze ND. [Sanfilippo Syndrome]. Vestn Ross Akad Med Nauk 2015: 419-27.
  • 4. Gaffke L, Pierzynowska K, Piotrowska E, Węgrzyn G. How close are we to therapies for Sanfilippo disease? Metab Brain Dis 2018; 33:1-10.
  • 5. Zelei T, Csetneki K, Vokó Z, Siffel C. Epidemiology of Sanfilippo syndrome: results of a systematic literature review. Orphanet J Rare Dis 2018; 13:53.
  • 6. Wilhelm CM, Truxal KV, McBride KL, Kovalchin JP, Flanigan KM. Natural history of echocardiographic abnormalities in mucopolysaccharidosis III. Mol Genet Metab 2018; 124:131-4.
  • 7. Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA. Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 2008; 31:240-52.
  • 8. Lin HY, Chen MR, Lin SM, et al. Cardiac characteristics and natural progression in Taiwanese patients with mucopolysaccharidosis III. Orphanet J Rare Dis 2019; 14:140.
  • 9. Leal GN, de Paula AC, Leone C, Kim CA. Echocardiographic study of paediatric patients with mucopolysaccharidosis. Cardiol Young 2010; 20:254-61.
  • 10. Braunlin EA, Harmatz PR, Scarpa M, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis 2011; 34:1183-97.
  • 11. Lopez L, Colan SD, Frommelt PC, et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the pediatric measurements writing group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr 2010; 23:465-95; quiz 576-7.
  • 12. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777-802.
  • 13. Lavery C, Hendriksz CJ, Jones SA. Mortality in patients with Sanfilippo syndrome. Orphanet J Rare Dis 2017; 12:168.
  • 14. Mitchell J, Berger KI, Borgo A, et al. Unique medical issues in adult patients with mucopolysaccharidoses. Eur J Intern Med 2016; 34:2-10.
  • 15. Meyer A, Kossow K, Gal A, et al. Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). Pediatri s 2007; 120:e1255-61. doi: 10.1542/ peds.2007-0282.
  • 16. Ruijter GJ, Valstar MJ, van de Kamp JM, et al. Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. Mol Genet Metab 2008; 93:104-11.
  • 17. Delgadillo V, O’Callaghan Mdel M, Gort L, Coll MJ, Pineda M. Natural history of sanfilippo syndrome in Spain. Orphanet J Rare Dis 2013; 8:189.
  • 18. Jansen AC, Cao H, Kaplan P, et al. Sanfilippo syndrome type D: natural history and identification of 3 novel mutations in the GNS Gene. Arch Neurol 2007; 64:1629-34.
  • 19. Beesley CE, Burke D, Jackson M, Vellodi A, Winchester BG, Young EP. Sanfilippo syndrome type D: identification of the first mutation in the N-acetylglucosamine-6-sulphatase gene. J Med Genet 2003; 40:192-4.
  • 20. Gross DM, Williams JC, Caprioli C, Dominguez B, Howell RR. Echocardiographic abnormalities in the mucopolysaccharide storage diseases. Am J Cardiol 1988; 61:170-6.
  • 21. Chen MR, Lin SP, Hwang HK, Yu CH. Cardiovascular changes in mucopolysaccharidoses in Taiwan. Acta Cardiol 2005; 60:51-3.
  • 22. Fesslová V, Corti P, Sersale G, et al. The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young 2009; 19:170-8.
APA bilginer gurbuz b, AYPAR E, ALEHAN D, tokatli a, coskun t, DURSUN A, Sivri H (2021). Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients. , 195 - 201. 10.4274/jpr.galenos.2021.65768
Chicago bilginer gurbuz berrak,AYPAR EBRU,ALEHAN DURSUN,tokatli aysegul,coskun turgay,DURSUN Ali,Sivri H. Serap Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients. (2021): 195 - 201. 10.4274/jpr.galenos.2021.65768
MLA bilginer gurbuz berrak,AYPAR EBRU,ALEHAN DURSUN,tokatli aysegul,coskun turgay,DURSUN Ali,Sivri H. Serap Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients. , 2021, ss.195 - 201. 10.4274/jpr.galenos.2021.65768
AMA bilginer gurbuz b,AYPAR E,ALEHAN D,tokatli a,coskun t,DURSUN A,Sivri H Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients. . 2021; 195 - 201. 10.4274/jpr.galenos.2021.65768
Vancouver bilginer gurbuz b,AYPAR E,ALEHAN D,tokatli a,coskun t,DURSUN A,Sivri H Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients. . 2021; 195 - 201. 10.4274/jpr.galenos.2021.65768
IEEE bilginer gurbuz b,AYPAR E,ALEHAN D,tokatli a,coskun t,DURSUN A,Sivri H "Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients." , ss.195 - 201, 2021. 10.4274/jpr.galenos.2021.65768
ISNAD bilginer gurbuz, berrak vd. "Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients". (2021), 195-201. https://doi.org/10.4274/jpr.galenos.2021.65768
APA bilginer gurbuz b, AYPAR E, ALEHAN D, tokatli a, coskun t, DURSUN A, Sivri H (2021). Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients. The Journal of Pediatric Research, 8(2), 195 - 201. 10.4274/jpr.galenos.2021.65768
Chicago bilginer gurbuz berrak,AYPAR EBRU,ALEHAN DURSUN,tokatli aysegul,coskun turgay,DURSUN Ali,Sivri H. Serap Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients. The Journal of Pediatric Research 8, no.2 (2021): 195 - 201. 10.4274/jpr.galenos.2021.65768
MLA bilginer gurbuz berrak,AYPAR EBRU,ALEHAN DURSUN,tokatli aysegul,coskun turgay,DURSUN Ali,Sivri H. Serap Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients. The Journal of Pediatric Research, vol.8, no.2, 2021, ss.195 - 201. 10.4274/jpr.galenos.2021.65768
AMA bilginer gurbuz b,AYPAR E,ALEHAN D,tokatli a,coskun t,DURSUN A,Sivri H Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients. The Journal of Pediatric Research. 2021; 8(2): 195 - 201. 10.4274/jpr.galenos.2021.65768
Vancouver bilginer gurbuz b,AYPAR E,ALEHAN D,tokatli a,coskun t,DURSUN A,Sivri H Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients. The Journal of Pediatric Research. 2021; 8(2): 195 - 201. 10.4274/jpr.galenos.2021.65768
IEEE bilginer gurbuz b,AYPAR E,ALEHAN D,tokatli a,coskun t,DURSUN A,Sivri H "Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients." The Journal of Pediatric Research, 8, ss.195 - 201, 2021. 10.4274/jpr.galenos.2021.65768
ISNAD bilginer gurbuz, berrak vd. "Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients". The Journal of Pediatric Research 8/2 (2021), 195-201. https://doi.org/10.4274/jpr.galenos.2021.65768